BTA biota holdings limited

What I find particularly interesting about the result is that...

  1. 173 Posts.
    What I find particularly interesting about the result is that Relenza was the third largest drug by revenue for GSK during the quarter, behind Seretide/Advair and Valtrex.

    GSK wont be able to ignore the very real importance of Relenza to its profitability and will drive Relenza sales a lot harder. Relenza sales will still be subject to flu seasons and government orders but, no doubt, extra support from GSK will go a long way in both markets.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.